Intralesional immunotherapy with purified protein derivative antigen in the treatment of multiple cutaneous warts: an open label study in an urban teaching hospital
Abstract
Background: Viral warts caused by human papilloma virus are a group of oncogenic viruses that result in verrucous growths on the skin and mucosae. Intralesional immunotherapy has been tried in recent years with success with the use of a variety of antigens to non-specifically stimulate the cell mediated immune response. Similarly, we undertook a study to evaluate the efficacy and safety of tuberculin purified protein derivative as an immunotherapeutic modality.
Methods: A total of 25 patients were included in the study. Each patient was injected with 2.5 TU of tuberculin PPD (0.04 ml) intralesionally into most of the warts at 2 weekly intervals for a maximum of six sessions. It is an interventional study with follow-up upto 6 months. Descriptive analysis was done with use of SPSS version 23 tool. Complete resolution of warts was considered as the clinical end point. Response was graded as excellent response (>80% resolution), good response (50-80%), fair response (20-50%) and no response (<20%).
Results: Out of the 25 patients, 14 patients showed excellent response (56%), 4 patients showed good response (16%), 5 patients showed fair response (20%) and 2 patients did not show any response (8%). Over 22 patients (88%) showed features of pain, erythema and inflammation at the injection site, whereas 3 patients (12%) developed itching at the site. The ‘faces’ pain rating scale was used to measure pain tolerance. An overall response rate (fair/good/ excellent) was given by 23 out of the 25 patients (92%), which proved satisfactory.
Conclusions: Intralesional immunotherapy with PPD effectively cures warts which are present locally and also at distant sites. It is safe, economic and efficacious.
Keywords
Full Text:
PDFReferences
Jaiswal A, Gupta K, Sharma RP, Bedi G. Immunotherapy with PPD in treatment of warts: An open labelled study from western Uttar Pradesh. IP Indian J Clin Exp Dermatol. 2019:5(1):41-5.
El-Khalawany M, Shaaban D, Aboeldahab S. Immunotherapy of viral warts: myth and reality. Egyptian J Dermatol Venerol. 2015;35(1):1.
Thappa DM, Chiramel MJ. Evolving role of immunotherapy in the treatment of refractory warts. Indian Dermatol Online J. 2016;7(5):364.
Eassa BI, Abou-Bakr AA, El-Khalawany MA. Intradermal injection of PPD as a novel approach of immunotherapy in anogenital warts in pregnant women. Dermatol Therap. 2011;24(1):137-43.
Kaimal S, Gopinath H, Premalatha V. Intralesional immunotherapy with purified protein derivative (PPD) for cryotherapy-resistant warts. Int J Dermatol. 2020;59(6):726-9.
Lipke, Michelle M. An armamentorium of wart treatments. Clin Med Res. 2006;4(4):273-93.
Chandra S, Sil A, Datta A, Pal S, Das NK. A double-blind, randomized controlled trial to compare the effectiveness and safety of purified protein derivative of tuberculin antigen with Mycobacterium w vaccine in the treatment of multiple viral warts. Indian J Dermatol Venereol Leprol. 2019;85:355-66.
SuganthyV, Tharini GK. Treatment of multiple warts: efficacy of homologous autoimplantation therapy and comparison of homologous autoimplantation therapy and cryotherapy with liquid nitrogen. Int J Res Dermatol. 2019;5:575-9.
Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose–response study. Allergy. 2006;61(2):202-5.
Avgerinou G, Gregoriou S, Rigopoulos D, Stratigos A, Kalogeromitros D, Katsambas A. Alopecia areata: topical immunotherapy treatment with diphencyprone. J European Acad Dermatol Venereol. 2008;22(3):320-3.
Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigomaligna. Clin Exp Dermatol. 2004;29(1):15-21.
Jaiswal A, Gupta K, Sharma RP, Bedi G. Immunotherapy with PPD in treatment of warts: An open labelled study from western Uttar Pradesh. IP Indian J Clin Exp Dermatol. 2019;5(1):41-5.
Nimbalkar A, Pande S, Sharma R, Borkar M. Tuberculin purified protein derivative immunotherapy in the treatment of viral warts. Indian J Drugs Dermatol. 2016;2(1):19.
Saoji V, Lade NR, Gadegone R, Bhat A. Immunotherapy using purified protein derivative in the treatment of warts: An open uncontrolled trial. Indian J Dermatol Venereol Leprol. 2016;82(1):42.
